Repeated responses of an elderly patient with high-risk myelodysplastic syndrome to sequential therapy with tipifarnib, 5-azacitidine, and decitabine.
Möller
Isabel
I
Blum
Sabine
S
Gattermann
Norbert
N
Haas
Rainer
R
Habersang
Kerstin
K
Germing
Ulrich
U
Kuendgen
Andrea
A
D000368:Aged; D000754:Anemia, Refractory, with Excess of Blasts / Q000188:drug therapy*; D001374:Azacitidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use*; D001554:Benzene / Q000009:adverse effects; D004248:DNA (Cytosine-5-)-Methyltransferases / Q000037:antagonists & inhibitors*; D000077209:Decitabine; D004359:Drug Therapy, Combination; D051231:Farnesyltranstransferase / Q000037:antagonists & inhibitors*; D056572:Histone Deacetylase Inhibitors; D006801:Humans; D008297:Male; D016273:Occupational Exposure; D010976:Platelet Count; D015363:Quinolones / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D013792:Thalidomide / Q000009:adverse effects / Q000627:therapeutic use; D014635:Valproic Acid / Q000627:therapeutic use
D056572:Histone Deacetylase Inhibitors; D015363:Quinolones; D013792:Thalidomide; D014635:Valproic Acid; D000077209:Decitabine; D004248:DNA (Cytosine-5-)-Methyltransferases; D051231:Farnesyltranstransferase; D001554:Benzene; D001374:Azacitidine; C402769:tipifarnib